Daraxonrasib Approved for Metastatic Pancreatic Cancer
Key Points FDA approved daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one
Read MoreKey Points FDA approved daraxonrasib (RASONQUE) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma after at least one
Read MoreKey Takeaways Autophagy modulation is emerging as a promising strategy to overcome cisplatin-resistant gastric cancer. Researchers identified several existing drugs
Read More